The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Moreover, the relaxin-3 receptor (RXFP3) has been implicated in aging-related diseases. Research indicates that RXFP3 can regulate DNA damage response and repair processes, which are critical as ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...